한글목차

약제 요약

Sagimet는 1일 1회 경구용 선택적 지방산 합성효소(FASN) 억제제인 Denifanstat(Denifunastat, 구 TVB-2640)를 NAFLD의 침습적 형태인 NASH 치료제로 개발하고 있습니다. 간에서 FASN을 통한 팔미틴산 합성 증가가 간 지방의 과잉 축적, 염증, 섬유화라는 세 가지 중요한 질환의 촉진인자로 알려져 있습니다.

지난 11월, Sagimet Biosciences는 NASH 환자를 대상으로 한 Denifanstat 임상 IIb상(FASCINATE-2)의 양호한 중간 데이터를 발표했습니다.

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 비알코올성 지방성 간염(NASH)용 Denifanstat에 대해 조사분석했으며, 시장 규모 예측 및 작용기서, 용법과 용량, 연구개발 활동 등의 정보를 제공하고 있습니다.

목차

제1장 리포트 서론

제2장 비알코올성 지방간염(NASH)에서 Denifanstat의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품의 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 치료법)

제5장 Denifanstat 시장 평가

• 비알코올성 지방간염(NASH)에서 Denifanstat 시장 전망
• 주요 7 시장의 분석
  • 주요 7 시장의 비알코올성 지방간염(NASH)용 Denifanstat 시장 규모
• 시장의 분석 : 국가별
  • 미국의 비알코올성 지방간염(NASH)용 Denifanstat 시장 규모
  • 독일의 비알코올성 지방간염(NASH)용 Denifanstat 시장 규모
  • 영국의 비알코올성 지방간염(NASH)용 Denifanstat 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"Denifanstat Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Denifanstat for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Denifanstat for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Denifanstat for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Denifanstat market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Sagimet is developing Denifanstat (formerly TVB-2640) as an oral, once-daily selective fatty acid synthase (FASN) inhibitor to treat NASH, an aggressive form of NAFLD. In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three key drivers of the disease: excess accumulation of liver fat, inflammation, and fibrosis.

In November 2022, Sagimet Biosciences announced positive interim data from its Phase IIb clinical trial (FASCINATE-2) with denifanstat in NASH patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Denifanstat description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Denifanstat regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Denifanstat research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Denifanstat.
• The report contains forecasted sales of Denifanstat for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Denifanstat in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Denifanstat Analytical Perspective by DelveInsight

• In-depth Denifanstat Market Assessment

This report provides a detailed market assessment of Denifanstat for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Denifanstat Clinical Assessment

The report provides the clinical trials information of Denifanstat for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Denifanstat dominance.
• Other emerging products for NASH are expected to give tough market competition to Denifanstat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Denifanstat in NASH.
• Our in-depth analysis of the forecasted sales data of Denifanstat from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Denifanstat in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Denifanstat?
• What is the clinical trial status of the study related to Denifanstat in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Denifanstat development?
• What are the key designations that have been granted to Denifanstat for NASH?
• What is the forecasted market scenario of Denifanstat for NASH?
• What are the forecasted sales of Denifanstat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Denifanstat for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Denifanstat Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Denifanstat Market Assessment

• 5.1. Market Outlook of Denifanstat in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Denifanstat in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Denifanstat in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Denifanstat in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Denifanstat in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Denifanstat in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Denifanstat in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Denifanstat in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Denifanstat in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options